Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer
NCT02375997 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 592
Last updated 2015-03-03
Summary
The majority of patients with newly diagnosed metastatic ESCC and gastric cancer patients experience a number of physical and psychosocial symptoms related to their cancer. Those patients endure the greatest level of distress from their disease relative to other cancer populations in China. Although new drugs have been applied in recent years, the median overall survival time of metastatic ESCC and GC patients are still around 12 months. Therefore, it is essential to maximize their quality of life (QOL) from the time of diagnosis. Multiple studies demonstrate that symptoms such as pain, fatigue, and anorexia are prevalent at diagnosis and worsen over time. As a result, suffering increases throughout the course of the illness. To be most effective, palliative care with intensive symptom management and psychosocial support should begin at the time of diagnosis, not once life-prolonging therapies have failed. And some studies have revealed that early palliative can even prolong the overall survival time in advanced lung cancer. The investigators then initiated a randomized phase III clinical trial with standard oncology care plus early palliative care or not in metastatic esophageal carcinoma and gastric cancer to observe whether the early palliative can improve the QOL and even prolong the overall survival time in those patients
Conditions
- Metastatic Esophageal Squamous Carcinoma
- Gastric Cancer
Interventions
- OTHER
-
Palliative care
Early nutrition intervention and psychological intervention
Sponsors & Collaborators
-
Peking University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-10-31
- Primary Completion
- 2017-10-31
- Completion
- 2018-10-31
Countries
- China
Study Locations
More Related Trials
-
Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer
NCT01704690 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Precision Palliative Care for Patients With Advanced Esophageal Cancer
NCT06787313 ·Status: RECRUITING
-
Early Integration of Palliative Care in Esophageal Cancer Patients
NCT02547142 ·Status: TERMINATED ·Phase: NA
-
Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial
NCT01051765 ·Status: UNKNOWN ·Phase: PHASE2
-
Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer
NCT02016274 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma
NCT03211377 ·Status: UNKNOWN
-
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
NCT06889402 ·Status: NOT_YET_RECRUITING
-
Detection of Circulating Tumor Tells as The Guidance of the Neoadjuvant Chemotherapy of Esophageal Cancer
NCT03005314 ·Status: UNKNOWN ·Phase: NA
-
Association of Nutritional Status With Immune Checkpoint Inhibitor Efficacy in Metastatic Metastatic Esophagogastric Cancer.
NCT06923020 ·Status: ENROLLING_BY_INVITATION
-
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
NCT05142709 ·Status: COMPLETED
-
Multimodal Functional Imaging Combined With Metabolomics in Predicting the Efficacy of nCRT for Locally Advanced ESCC
NCT04759235 ·Status: UNKNOWN
-
Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRT
NCT06598917 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus
NCT01225523 ·Status: COMPLETED ·Phase: PHASE1
-
Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer
NCT02325986 ·Status: UNKNOWN ·Phase: PHASE2
-
Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer
NCT00154700 ·Status: COMPLETED ·Phase: PHASE2
-
Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
NCT07016737 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
NCT07312578 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
NCT02358863 ·Status: TERMINATED ·Phase: NA
-
High-dose Intensity Modulated Radiotherapy and Concurrent Chemotherapy in Esophageal Cancer
NCT03535207 ·Status: UNKNOWN ·Phase: NA
-
Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study
NCT05381636 ·Status: UNKNOWN ·Phase: PHASE2
-
Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China
NCT05194371 ·Status: COMPLETED
-
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
NCT06190782 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
NCT07016724 ·Status: RECRUITING ·Phase: PHASE2
-
Chemoradiotherapy in Unresectable Esophageal Cancer
NCT04278287 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.
NCT00209716 ·Status: COMPLETED ·Phase: PHASE1/PHASE2